Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03577782|
Recruitment Status : Unknown
Verified June 2018 by Luis F. Lopez-Cortes, Hospitales Universitarios Virgen del Rocío.
Recruitment status was: Recruiting
First Posted : July 5, 2018
Last Update Posted : July 5, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Biological: Entyvio (Vedolizumab)||Phase 1 Phase 2|
HIV cannot be eradicated and keep latent in anatomical and cellular reservoirs. In fact, patients undergoing antiretroviral treatment (ART) interruption rapidly experience plasma viral load rebound. The current alternative therapeutic strategies to antiretroviral treatment have the aim to achieve the eradication or permanent remission of plasma viral load, also known as functional cure, in the absence of ART, as occurs in persistent HIV controllers. In this scenario, new drugs associated to ART that allow the achievement of permanent plasma viral remission after ART withdrawn are needed.
The main targets of HIV infection are the memory CD4+ T-cells. This cell subset is mainly located in gut associated lymphoid tissue (GALT). These lymphocytes are recruited to the gut thanks to the expression of the integrin α4β7. The Env protein gp120 binds to α4β7 and enable the dissemination of HIV in the gut. At the same time the envelope of HIV is enriched in α4β7 coming from the plasma membrane of the host cells favoring its pathogenicity. Recently, the administration of a monoclonal antibody against α4β7 was shown to achieve significant protection for HIV transmission before and after low dose intravaginal inoculation of SIV in Rhesus Macaques. Surprisingly, long-term virological protection has been documented in SIV-infected macaques after ART interruption after administration and withdrawal of the monoclonal antibody against α4β7. The mechanisms through which this antibody has achieved the permanent remission of plasma viral load are not fully understood. The success of these findings in the simian model makes the antibody against α4β7 a good candidate as ART adjuvant with the aim to reach a functional cure and/or persistent virological remission in humans. Currently, there is a monoclonal antibody against α4β7 with known safety and security profiles in humans, this antibody is commercially available under the name of Vedolizumab. This antibody is used for the treatment of ulcerative colitis and Crohn Disease. In fact, there are already two clinical trials that are using Vedolizumab in HIV-infected patients (NCT02788175 y NCT03147859). In these clinical trials Vedolizumab is administered in the chronic phase of the infection in subjects with undetectable viral load during at least two years on ART. There are not clinical trials administering Vedolizumab in early stages of infection in naïve HIV-infected subjects for ART. Potentially, this strategy of early antibody treatment may increase the success of the therapy and decrease the time on ART of the individuals. The aim of the present clinical trial is to evaluate the safety and efficacy of Vedolizumab combined with ART to achieve permanent virological remission in naïve HIV-infected individuals after ART interruption.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increases above 10e5 HIV-RNA copies/mL (two consecutive measurements).|
|Masking:||None (Open Label)|
|Official Title:||Phase II Clinical Trial to Analyze the Safety and Efficacy of Vedolizumab Combined With Antiretroviral Therapy to Achieve Permanent Virological Remission in HIV-infected Subjects Without Previous Antiretroviral Therapy|
|Estimated Study Start Date :||September 2018|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||May 2020|
Experimental: Single group
HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
Biological: Entyvio (Vedolizumab)
At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
Patients will be followed up until week 48.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 48 weeks ]The number of adverse events and severity during Vedolizumab infusions and during all the follow up.
- Plasma viral load rebound or remision after interrupting Vedolizumab infusions and ART [ Time Frame: 48 weeks ]Quantitative plasma viral load (Roche HIV-1 RNA Viral Load Assay) measured before and after interrupting Vedolizumab infusions and ART.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Women during pregnancy or breast-feeding will be excluded. Women must agree to use suitable contraception method (hormonal or barrier method of birth control; abstinence) before entry and during the study.|
|Accepts Healthy Volunteers:||No|
- Individuals with documented HIV-infection. Aged, 18 - 65 years.
- HIV-RNA >1x10e4 copies/mL.
- CD4+ T-cell counts >350 cells//μL
- To accept analytical ART interruption.
- Presence of major resistance mutations to the antiretrovirals used.
- Active opportunistic infections.
- Pregnancy or breastfeeding
- Active hepatitis C or B virus infection.
- Active or latent tuberculosis not treated.
- Cirrhosis, portal hypertension and/or hypersplenism of any etiology.
- Current or past neoplasia susceptible to be treated with steroids, immunotherapy or chemotherapy.
- Abnormal laboratory measurements grade 3 or 4.
- Concomitant use of drugs with pharmacological interactions with the treatment of the study based on the technical data sheet of the products.
- Creatinine clearance <50mL/min.
- Any type of vaccination (e.g., hepatitis B virus, influenza…) two weeks before the beginning of the study.
- Cardiovascular disease (e.g., acute coronary syndrome, heart failure…).
- Neurological or neuro psychiatric disorder which symptoms may interfere with the safety and tolerability analysis.
- Alcohol abuse and/or drugs that may interfere with the study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03577782
|Contact: Ezequiel Ruiz-Mateos, PhDemail@example.com|
|Virgen del Rocío University Hospital||Recruiting|
|Seville, Spain, 41013|
|Contact: Sofia Rubio, PhD +34955012010 firstname.lastname@example.org; email@example.com|
|Principal Investigator: Ezequiel Ruiz-Mateos|
|Principal Investigator:||Ezequiel Ruiz-Mateos, PhD||Virgen del Rocio University Hospital|
|Responsible Party:||Luis F. Lopez-Cortes, Senior Researcher Andalusian Health System, Hospitales Universitarios Virgen del Rocío|
|Other Study ID Numbers:||
2018-000497-30 ( EudraCT Number )
|First Posted:||July 5, 2018 Key Record Dates|
|Last Update Posted:||July 5, 2018|
|Last Verified:||June 2018|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
RNA Virus Infections
Immunologic Deficiency Syndromes
Immune System Diseases